ArticleJournal of ginseng research2026
Ginsenoside Rs3 (G-Rs3) inhibits agonist- and oxLDL-mediated platelet activation and attenuates
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing flavonoids as innovative agents for the modulation of platelet activation and thrombotic disorders.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Platelet hyperactivation and thrombo-inflammatory processes are critical drivers of cardiovascular diseases. Although conventional antiplatelet therapies reduce thrombotic risk, their use is limited by bleeding complications and drug resistance. Ginsenoside Rs3 (G-Rs3) exhibits anti-inflammatory potential; however, the specific mechanisms underlying the antiplatelet and thrombo-inflammatory activity of ginsenoside Rs3 (G-Rs3) remain unclear. Methods: Human platelets were treated with G-Rs3 Results: G-Rs3 inhibited platelet aggregation in a dose-dependent manner following stimulation with collagen, thrombin, and U46619. It suppressed Ca Conclusion: These findings highlight G-Rs3 as a novel natural antithrombotic agent with anti-thrombo-inflammatory properties. Further studies are required to determine its translational potential and establish its therapeutic viability and safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.